Therapeutic Approaches for Duchenne Muscular Dystrophy: Old and New

被引:21
|
作者
Mackenzie, Samuel J. [1 ,2 ]
Nicolau, Stefan [1 ]
Connolly, Anne M. [1 ,2 ]
Mendell, Jerry R. [1 ,2 ]
机构
[1] Nationwide Childrens Hosp, Ctr Gene Therapy, Columbus, OH 43205 USA
[2] Ohio State Univ, Dept Pediat & Neurol, Columbus, OH 43210 USA
关键词
NATURAL-HISTORY; DOUBLE-BLIND; MUSCLE FUNCTION; MOUSE MODEL; DMD; PREDNISONE; TRIAL; GENE; EXPRESSION; SKELETAL;
D O I
10.1016/j.spen.2021.100877
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Duchenne muscular dystrophy (DMD) is marked by pathogenic variants in the DMD gene, leading to reduced or absent dystrophin translation, muscle fiber destruction, loss of ambulation, cardiomyopathy, respiratory failure, and eventually death. Disease progression is slowed with use of prednisone or other corticosteroid agents. Gene replacement therapy, which is one of the focus points of this review, has emerged as the most promising potential treatment for DMD, though alternative RNA-based strategies have been employed for patients with specific pathogenic variants. While challenges remain, many of these novel therapeutic approaches hold promise for treating this devastating disease. (C) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Duchenne muscular dystrophy: Current state and therapeutic perspectives
    Le Guen, Y. T.
    Le Gall, T.
    Laurent, V
    D'Arbonneau, F.
    Braun, S.
    Montier, T.
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2021, 205 (05): : 509 - 518
  • [42] Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular Dystrophy
    Krishna, Lakshmi
    Prashant, Akila
    Kumar, Yogish H.
    Paneyala, Shasthara
    Patil, Siddaramappa J.
    Ramachandra, Shobha Chikkavaddaragudi
    Vishwanath, Prashant
    NEUROLOGY INTERNATIONAL, 2024, 16 (04): : 731 - 760
  • [43] Molecular Therapeutic Strategies Targeting Duchenne Muscular Dystrophy
    Mendell, Jerry R.
    Rodino-Klapac, Louise R.
    Malik, Vinod
    JOURNAL OF CHILD NEUROLOGY, 2010, 25 (09) : 1145 - 1148
  • [44] Potential therapeutic action of adiponectin in Duchenne muscular dystrophy
    Abou-Samra, M.
    Boursereau, R.
    Noel, L.
    Brichard, S.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S129 - S129
  • [45] THERAPEUTIC TRIAL OF ISAXONINE IN DUCHENNE MUSCULAR-DYSTROPHY
    HECKMATT, JZ
    HYDE, SA
    GABAIN, A
    DUBOWITZ, V
    MUSCLE & NERVE, 1988, 11 (08) : 836 - 847
  • [46] Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy
    Happi Mbakam, Cedric
    Lamothe, Gabriel
    Tremblay, Jacques P.
    FRONTIERS IN MEDICINE, 2022, 9
  • [47] Duchenne muscular dystrophy: disease mechanism and therapeutic strategies
    Angulski, Addeli Bez Batti
    Hosny, Nora
    Cohen, Houda
    Martin, Ashley A.
    Hahn, Dongwoo
    Bauer, Jack
    Metzger, Joseph M.
    FRONTIERS IN PHYSIOLOGY, 2023, 14
  • [48] Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy
    Wong, Tatianna Wai Ying
    Cohn, Ronald D.
    CURRENT GENE THERAPY, 2017, 17 (04) : 301 - 308
  • [49] Potential therapeutic targets for hypotension in duchenne muscular dystrophy
    Saxena, Harshi
    Weintraub, Neal L.
    Tang, Yaoliang
    MEDICAL HYPOTHESES, 2024, 185
  • [50] Duchenne Muscular dystrophy: from pathogenesis to therapeutic trials
    Muntoni, F
    NEUROMUSCULAR DISORDERS, 2004, 14 (8-9) : 612 - 612